<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5513">
  <stage>Registered</stage>
  <submitdate>21/08/2008</submitdate>
  <approvaldate>21/08/2008</approvaldate>
  <nctid>NCT00740129</nctid>
  <trial_identification>
    <studytitle>Re-treatment of Patients With Paget's Disease Using Zoledronic Acid</studytitle>
    <scientifictitle>An Open Label, Reclast®/Aclasta®, Re-treatment of Relapsed Patients With Paget's Disease of Bone Who Participated in the CZOL446K2304 and CZOL446K2305 Core Registration Studies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CZOL446K2418</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Paget's Disease of the Bone</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Zoledronic Acid

Other: 1 - Open label, single arm treatment study


Treatment: drugs: Zoledronic Acid
Zoledronic acid 5 mg intravenous infusion once

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Normalization of total serum alkaline phosphatase within 6 months after a single 5 mg re-treatment dose of zoledronic acid</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Collect information pertaining to relapse diagnosis to define retreatment guidelines for Paget's disease</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in SAP levels relative to baseline</outcome>
      <timepoint>3 &amp; 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Collect adverse events profile for re-treated patients</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written Informed Consent

          -  Patients with Paget's disease randomized to the zoledronic acid arm from the
             CZOL446K2304 and CZOL446K2305 core studies and who were responders by 6 months

          -  Confirmed relapse of Paget's disease of bone (i.e. SAP above ULN, bone scan, worsening
             clinical symptoms)</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  A patient previously treated with zoledronic acid who relapsed and was retreated with
             anti-resorptive bisphosphonate or calcitonin therapy within the last 12 months

          -  Bisphosphonate Hypersensitivity

          -  Patients with suspected/proven metastases at re-treatment

          -  Calculated creatinine clearance &lt;35 mL/min at screening

          -  Serum calcium level &lt;2.07 mmol/L at screening

          -  Active primary hyperparathyroidism, hyperparathyroidism, hypoparathyroidism or
             hypothyroidism

        Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>6</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Aukland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to demonstrate that patients with Paget's disease of the bone
      who had responded to zoledronic acid treatment as participants in the core registration
      studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully
      treated with a 5mg infusion of zoledronic acid.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00740129</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>